Clinical trials
Phase 4 Hyperparathyroidism, Secondary trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
42 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 6 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 6 |
| 2010 | 6 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 34 |
| Terminated | 5 |
| Unknown status | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Abbott | 7 |
| Amgen | 7 |
| Genzyme, a Sanofi Company | 4 |
| Papageorgiou General Hospital | 2 |
| The University of Hong Kong | 2 |
| AbbVie (prior sponsor, Abbott) | 1 |
| Chulalongkorn University | 1 |
| Clalit Health Services | 1 |
| Duke University | 1 |
| Emory University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hyperparathyroidism, Secondary | 42 |
| Renal Insufficiency, Chronic | 15 |
| Kidney Failure, Chronic | 7 |
| Hypercalcemia | 5 |
| Hyperparathyroidism | 5 |
| Renal Insufficiency | 4 |
| Vitamin D Deficiency | 4 |
| Hyperphosphatemia | 3 |
| Calcinosis | 2 |
| Chronic Kidney Disease-Mineral and Bone Disorder | 2 |
Trials
Showing 76 to 42 of 42. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.